KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Shares Outstanding (2018 - 2025)

Aurinia Pharmaceuticals' Shares Outstanding history spans 8 years, with the latest figure at $132.3 million for Q4 2025.

  • For Q4 2025, Shares Outstanding fell 6.08% year-over-year to $132.3 million; the TTM value through Dec 2025 reached $132.3 million, down 6.08%, while the annual FY2025 figure was $132.3 million, 6.08% down from the prior year.
  • Shares Outstanding reached $132.3 million in Q4 2025 per AUPH's latest filing, roughly flat from $131.8 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $143.8 million in Q4 2023 to a low of $128.1 million in Q1 2021.
  • Average Shares Outstanding over 5 years is $138.7 million, with a median of $141.8 million recorded in 2022.
  • Peak YoY movement for Shares Outstanding: increased 13.92% in 2021, then dropped 7.87% in 2025.
  • A 5-year view of Shares Outstanding shows it stood at $141.6 million in 2021, then grew by 0.47% to $142.3 million in 2022, then grew by 1.1% to $143.8 million in 2023, then dropped by 2.05% to $140.9 million in 2024, then fell by 6.08% to $132.3 million in 2025.
  • Per Business Quant, the three most recent readings for AUPH's Shares Outstanding are $132.3 million (Q4 2025), $131.8 million (Q3 2025), and $132.7 million (Q2 2025).